2017 American Transplant Congress
Induction Treatment with Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplant Recipients with Planned Early Steroid Withdrawal.
Transplant Surgery, Brigham and Women's Hospital, Boston
Introduction: In a previous study by our group, rabbit antithymocyte globulin (r-ATG) induction was associated with lower rates of rejection when compared to basiliximab in…2017 American Transplant Congress
IL-7 Receptor Heterogeneity as a Mechanism for Repertoire Change During Post-Depletional Homeostatic Proliferation and Its Relation to Costimulation Blockade Resistant Rejection.
Department of Surgery, Duke University School of Medicine, Durham, NC
Transplant patients treated with belatacept without depletional induction show high rates of costimulation blockade resistant rejection (CoBRR); this has been associated with CD57+ T cells.…2017 American Transplant Congress
The Impact of Induction Therapy on Delayed Graft Function Following Kidney Transplantation in Mated Kidneys.
Department of Transplantation, Albert Einstein-Montefiore, Bronx, NY
Purpose: Delayed graft function (DGF) is defined as the need for dialysis within one week of transplantation and occurs in 20-50% of deceased-donor kidney transplant…2017 American Transplant Congress
Risk of Primary Central Nervous System Lymphoma in Solid Organ Transplant Recipients.
National Cancer Institute, Bethesda, MD
Background: Risk of primary central nervous system lymphoma (PCNSL) is greatly increased in immunosuppressed HIV-infected people. Case series describe PCNSL in solid organ transplant (SOT)…2017 American Transplant Congress
Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy.
The need for using induction therapy in de novo non-HLA sensitized kidney-transplant patients receiving tacrolimus-based therapy is a matter of debate. The aims of this…2016 American Transplant Congress
The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.
Efficacy of CNI- and corticosteroid-free immunosuppressive regimens has not been demonstrated in large, multicenter trials. BEST (Belatacept-based Early Steroid Withdrawal Trial) (NCT 01729494) compares 2…2016 American Transplant Congress
Serum Levels of Soluble Myeloid Antigens After Kidney Allograft Transplantation.
Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
Mononuclear phagocytes and neutrophils play a key role in early responses against the transplanted kidney allograft. It is expected that during the reperfusion of kidney…2016 American Transplant Congress
B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin.
Purpose: B cell subsets could be used as biomarkers to modulate therapy regimens in kidney transplant patients. B cell subsets occur with varying proportions within…2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.
CNI delay early after heart transplantation is a recommended therapeutic option according to ISHLT guidelines. However, there exist only few published data on feasibility of…2016 American Transplant Congress
Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections.
Introduction: 3C study concluded that in comparison to basiliximab, alemtuzumab induction reduces the risk of biopsy proven acute rejection (BPAR) in renal transplant recipients. In…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 31
- Next Page »